A PSEN1 genetic test for a dementia second opinion typically costs $0 to $1,000 out of pocket, with insurance usually covering it only when a relative's mutation is already known. PSEN1 is one of three genes — alongside APP and PSEN2 — tied to early-onset, inherited Alzheimer's disease, and a second-opinion specialist will ask specific questions before ordering or repeating this test. Getting a clear answer before the appointment means understanding what the lab charges, what your insurer will actually pay for, and what counseling has to happen first. The sections below walk through each of those pieces so you can walk into a second-opinion visit prepared rather than guessing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does PSEN1 testing actually cost?
- When will insurance actually pay for it?
- Why PSEN1 results change how urgently you act
- What has to happen before you get a result
- What a negative result does — and doesn't — rule out
- What insurance protections do and don't cover
- Frequently Asked Questions
What does PSEN1 testing actually cost?
Without insurance, expect a list price near $990 for either a PSEN1-only test or the broader three-gene APP/PSEN1/PSEN2 panel, according to PreventionGenetics' test catalog. That figure is useful as a cash benchmark if you're paying directly or comparing labs.
With insurance in the picture, the number usually drops. A 2025 presentation from the University of Wisconsin–Madison's Dementia Diagnosis & Care Network reported that patients typically pay $0 to $1,000 out of pocket for monogenic Alzheimer's gene panels, with many landing closer to $300 after insurance adjustments, according to the UW–Madison Dementia Diagnosis & Care Network. The gap between the list price and the typical out-of-pocket figure comes down almost entirely to whether the test meets your insurer's coverage criteria.
When will insurance actually pay for it?
Coverage hinges on one distinction: whether a PSEN1 mutation has already been identified in a relative, or whether you're asking for open-ended testing with no known family variant. FEP Blue's January 2026 medical policy treats targeted testing for a single, already-identified PSEN1, PSEN2, or APP variant as potentially medically necessary even in someone without symptoms, while it classifies broader panel testing with no known family mutation as investigational, according to Federal Employee Program Blue's medical policy.
Blue Cross NC applies a similar logic but adds a reproductive carve-out: it covers APP/PSEN1/PSEN2 testing in people without symptoms when the result will inform reproductive decisions, including for a first-degree relative — a parent, sibling, or child — of someone with a confirmed mutation, according to Blue Cross NC's policy. Outside those known-variant or reproductive-planning scenarios, many commercial insurers still label broader APP/PSEN1/PSEN2/APOE panel testing as experimental or investigational, according to NCRAD's patient-facing guidance.
- Ask your second-opinion provider: has a specific PSEN1 variant already been confirmed in a relative, or would this be exploratory testing?
- If exploratory, ask whether reproductive planning is a documented reason for the test — some policies cover it on that basis alone.
- Request the exact policy name and number your insurer will use to review the claim, so you can check it against the test being ordered.
Why PSEN1 results change how urgently you act
PSEN1 mutations are essentially fully penetrant — close to 100% of carriers go on to develop the disease — compared with roughly 95% for PSEN2, according to Blue Cross NC's policy. The same policy notes that PSEN1 carriers typically become symptomatic more than a decade earlier than PSEN2 carriers.
That difference matters for how a second opinion should be paced. A confirmed or suspected PSEN1 variant points toward a faster workup and earlier conversations about planning, while a PSEN2 finding may allow more time. A second-opinion specialist weighing which gene is most likely involved should be factoring in this timeline difference, not treating all three genes as interchangeable.
What has to happen before you get a result
The 2011 joint statement from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors says APP/PSEN1/PSEN2 testing may be offered to people with early-onset or suspected autosomal-dominant Alzheimer's, but it requires a physician's order and bars testing in anyone under 18, according to the ACMG/NSGC guideline. That rules out ordering the test on your own initiative, and it rules out testing a minor even within a known-mutation family.
Insurer medical policy adds another checkpoint: Highmark's commercial medical policy and ARUP Laboratories' own test consent form both require in-person pretest and posttest genetic counseling, delivered by the ordering provider or a genetic counselor, before PSEN1/PSEN2/APP results are disclosed, according to Highmark's medical policy. When you're seeking a second opinion, ask directly whether that counseling took place the first time and whether the new provider will repeat it.
- Confirm a physician actually ordered the original test, not a direct-to-consumer kit.
- Ask whether pretest and posttest counseling happened, and with whom.
- If no counseling occurred, expect the second-opinion provider to require it before releasing or reinterpreting results.
What a negative result does — and doesn't — rule out
A negative PSEN1/PSEN2/APP result doesn't close the question. ARUP Laboratories reports that disease-causing variants in these three genes are found in only 60% to 80% of early-onset Alzheimer's cases that get tested, according to ARUP Laboratories' test directory.
That means one in five to two in five cases with a strong genetic pattern still come back negative on this panel. This is the most common reason a second opinion revisits genetic testing: a prior negative result in someone with a clear family history of early-onset disease may call for expanded testing or a fresh review of how the original result was interpreted, rather than accepting the negative at face value.
What insurance protections do and don't cover
Federal law limits how a PSEN1 result can be used against you, but the protection has real gaps. Under the Genetic Information Nondiscrimination Act (GINA), health insurers cannot use a PSEN1 result to deny you coverage or raise your premiums, according to NPR's reporting on GINA.
That protection does not extend to life, disability, or long-term-care insurance, which may legally request genetic results before issuing a policy. If you're weighing whether to pursue testing as part of a second opinion, it's worth applying for any life, disability, or long-term-care coverage you want before the test is run, since those insurers can factor a known result into their decision afterward.
Frequently Asked Questions
Does a PSEN1 test cost the same everywhere?
List prices cluster near $990, but what patients actually pay depends on insurance adjustment — commonly $0 to $1,000, often near $300, according to the UW–Madison Dementia Diagnosis & Care Network.
Can a minor be tested for PSEN1 even if a parent has a confirmed mutation?
No. The ACMG/NSGC guideline bars testing anyone under 18 regardless of family history, according to the ACMG/NSGC guideline.
If my test was negative, does that mean I don't have a genetic form of Alzheimer's?
Not necessarily — ARUP Laboratories finds disease-causing variants in only 60% to 80% of tested early-onset cases, according to ARUP Laboratories' test directory.
Can a life insurance company ask about my PSEN1 result?
Yes. GINA protects health insurance decisions but not life, disability, or long-term-care insurance, according to NPR's reporting on GINA.
